Last reviewed · How we verify
TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen is a Aromatase inhibitor, Selective estrogen receptor modulator Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 3 development for Treatment of hormone receptor-positive metastatic breast cancer, Adjuvant treatment of hormone receptor-positive breast cancer.
Letrozole and Anastrozole are non-steroidal, selective aromatase inhibitors, while Tamoxifen is a selective estrogen receptor modulator.
Letrozole and Anastrozole are non-steroidal, selective aromatase inhibitors, while Tamoxifen is a selective estrogen receptor modulator. Used for Treatment of hormone receptor-positive metastatic breast cancer, Adjuvant treatment of hormone receptor-positive breast cancer.
At a glance
| Generic name | TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Aromatase inhibitor, Selective estrogen receptor modulator |
| Target | Aromatase, Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
These drugs work by inhibiting the aromatase enzyme, which is responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body. Tamoxifen, on the other hand, binds to estrogen receptors, blocking the action of estrogen in breast tissue.
Approved indications
- Treatment of hormone receptor-positive metastatic breast cancer
- Adjuvant treatment of hormone receptor-positive breast cancer
Common side effects
- Hot flashes
- Vaginal discharge
- Nausea
- Diarrhea
- Musculoskeletal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen CI brief — competitive landscape report
- TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
What is TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen?
How does TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen work?
What is TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen used for?
Who makes TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen?
What drug class is TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen in?
What development phase is TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen in?
What are the side effects of TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen?
What does TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen target?
Related
- Drug class: All Aromatase inhibitor, Selective estrogen receptor modulator drugs
- Target: All drugs targeting Aromatase, Estrogen receptor
- Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of hormone receptor-positive metastatic breast cancer
- Indication: Drugs for Adjuvant treatment of hormone receptor-positive breast cancer